Big pharma, Partnering, Pharma

Pfizer has signed a biotech deal with Sepha

Posted on 05 June 2014

Tags: , ,

Sepha has clinched a $1.5M export contract with the world's largest pharmaceutical company, Pfizer, to supply its proprietary technology, VisionScan, for the non-destructive seal and leak detection of Pfizer's blister packs.

VisionScan was designed by Sepha's Product Development team at its East Belfast facility two years ago.

It uses high resolution imaging technology and was developed to replace the traditional manual test for leaks in pharmaceutical packaging such as blister packs which is destructive and renders packs unusable.

The agreement makes Sepha the preferred supplier of non destructive testing for Pfizer and consolidates VisionScan's progress in fast becoming the world-class standard for leak testing.

For further deal information visit Current Agreements (subscription required)


Report: Partnering Deals and Alliances with Pfizer

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply